FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
NEW YORK, March 17, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Natus Medical Incorporated (“Natus”) (NASDAQ:BABY) between October 16, 2015 and April 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. To get more information go to:
http://www.zlk.com/pslra/natus-medical-incorporated
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis.
If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
